Pitch deck: SparingVision raises $75 million for CRISPR eye treatments

SparingVision
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

20
every slide · same image gating as the playbook
01
Slide 1
front_matter
02
The slide uses a four-column layout to summarize the company's core value propositions.summarize
Open slide detailLoop · Golden Circle
03
The timeline is divided into two phases: 'Foundation of the story' and 'Acceleration of the story'.show_traction
Open slide detailLoop · Golden Circle
04
other
Open slide detailLoop · Golden Circle
05
The slide uses a three-column layout to represent the strategic pillars.present_framework
Open slide detailLoop · Golden Circle
06
The slide uses a pipeline table format to categorize products by development stage (Preclinical Discovery vs IND Enabling).plan_implementation
07
Uses a visual metaphor of a painting to illustrate the loss of vision over time.establish_context
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
The slide uses a biological process diagram to show how different therapies target specific stages of retinal degeneration.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
The slide uses conceptual line charts to illustrate the difference between restorative gene therapy (like Luxturna) and neuroprotective/slowing therapies (like present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
The slide uses a biological process diagram to illustrate the mechanism of action.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
The slide illustrates the molecular biology design of the therapeutic vector.present_solution
Open slide detailBeat · Product
12
The slide uses histological imagery to validate the disease model's progression speed.establish_context
13
Includes a timeline of the experiment, a bar chart of visual acuity thresholds, and representative microscopy images of cone density.show_traction
Open slide detailBeat · Traction
14
The slide uses a biological process diagram to explain the mechanism of action for a gene therapy product.present_solution
Open slide detailBeat · Traction
15
The data demonstrates functional rescue in a retinitis pigmentosa (RP) mouse model.show_traction
Open slide detailBeat · Traction
16
The slide uses a three-column layout to explain the 'why' behind the partnership, followed by a summary box on the right.illustrate_case
17
The slide illustrates the mechanism of action for in vivo genome editing in the retina.present_solution
18
The slide uses a process-like flow to illustrate a multi-criteria decision framework.present_framework
19
The slide uses a numbered list format to present strategic milestones.plan_implementation
Open slide detailBeat · Market Size
20
This is a closing contact slide.other